Efficacy of immediate-release oxycodone for dyspnoea in cancer patient: cancer dyspnoea relief (CDR) trial
Guidelines recommend morphine as the first-line pharmacological treatment for cancer dyspnoea. However, trials with other opioids have not been performed. Our aim was to demonstrate the non-inferiority of oxycodone to morphine for relieving dyspnoea in cancer patients. We conducted a multicentre, op...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of clinical oncology 2018-12, Vol.48 (12), p.1070-1075 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1075 |
|---|---|
| container_issue | 12 |
| container_start_page | 1070 |
| container_title | Japanese journal of clinical oncology |
| container_volume | 48 |
| creator | Yamaguchi, Takashi Matsuda, Yoshinobu Matsuoka, Hiromichi Hisanaga, Takayuki Osaka, Iwao Watanabe, Hiroaki Maeda, Isseki Imai, Kengo Tsuneto, Satoru Wagatsuma, Yukiko Kizawa, Yoshiyuki |
| description | Guidelines recommend morphine as the first-line pharmacological treatment for cancer dyspnoea. However, trials with other opioids have not been performed. Our aim was to demonstrate the non-inferiority of oxycodone to morphine for relieving dyspnoea in cancer patients.
We conducted a multicentre, open-label, parallel-group, randomized control trial. We randomly and equally assigned cancer patients on regular oxycodone who developed dyspnoea to get a single dose of oral immediate-release oxycodone or morphine. We evaluated the change in dyspnoea intensity (numeric rating scale: 0-10) and adverse events after the medication administration.
This study was preconfidence interval -maturely terminated. All 17 enroled patients (8 using oxycodone, 9 using morphine) completed evaluations. In the oxycodone group, dyspnoea intensity decreased 1.75 points [95% confidence interval, 0.72-2.78] at 60 min and 1.50 points (95% confidence interval, -0.11 to 3.11) at 120 min. In the morphine group, dyspnoea decreased 1.33 points (95% confidence interval, 0.41-2.25) at 60 min and 1.00 point (95% confidence interval, -0.08 to 2.08) at 120 min. The differences did not fulfil the non-inferiority requirement. Although two and four patients in morphine group developed drowsiness at 60 and 120 min, no patient in oxycodone group developed significant adverse events.
Although we did not show the non-inferiority of oxycodone, oxycodone may have some effectiveness for cancer dyspnoea without significant safety concern.
UMIN-CTR: UMIN 000005760. |
| doi_str_mv | 10.1093/jjco/hyy139 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2113268653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2113268653</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-628135460cf3b938142c7425bea54ef995a57475c9f578ede5984ce627c3239f3</originalsourceid><addsrcrecordid>eNpNkEtLw0AURgdRbK2u3MssKxI7zyTjTmp9QEEQXYfp5A5OSDJ1JgXz703pA1f3u3A4i4PQNSX3lCg-qyrjZ999T7k6QWMqUpnwlNHTf3uELmKsCCEyF9k5GnHCUsKVGqNqYa0z2vTYW-yaBkqnO0gC1KAjYP_bG1_6FrD1AZd9XLceNHYtNro1EPBadw7a7uHwH5HB4MDi6fzp4xZ3wen6Ep1ZXUe42t8J-npefM5fk-X7y9v8cZkYIViXpCynXIqUGMtXiudUMJMJJlegpQCrlNQyE5k0ysoshxKkyoWBlGWGM64sn6DpzrsO_mcDsSsaFw3UtW7Bb2LBKOUszVPJB_Ruh5rgYwxgi3VwjQ59QUmxjVts4xa7uAN9sxdvVkOoI3uoyf8AX7R2UA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2113268653</pqid></control><display><type>article</type><title>Efficacy of immediate-release oxycodone for dyspnoea in cancer patient: cancer dyspnoea relief (CDR) trial</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yamaguchi, Takashi ; Matsuda, Yoshinobu ; Matsuoka, Hiromichi ; Hisanaga, Takayuki ; Osaka, Iwao ; Watanabe, Hiroaki ; Maeda, Isseki ; Imai, Kengo ; Tsuneto, Satoru ; Wagatsuma, Yukiko ; Kizawa, Yoshiyuki</creator><creatorcontrib>Yamaguchi, Takashi ; Matsuda, Yoshinobu ; Matsuoka, Hiromichi ; Hisanaga, Takayuki ; Osaka, Iwao ; Watanabe, Hiroaki ; Maeda, Isseki ; Imai, Kengo ; Tsuneto, Satoru ; Wagatsuma, Yukiko ; Kizawa, Yoshiyuki</creatorcontrib><description>Guidelines recommend morphine as the first-line pharmacological treatment for cancer dyspnoea. However, trials with other opioids have not been performed. Our aim was to demonstrate the non-inferiority of oxycodone to morphine for relieving dyspnoea in cancer patients.
We conducted a multicentre, open-label, parallel-group, randomized control trial. We randomly and equally assigned cancer patients on regular oxycodone who developed dyspnoea to get a single dose of oral immediate-release oxycodone or morphine. We evaluated the change in dyspnoea intensity (numeric rating scale: 0-10) and adverse events after the medication administration.
This study was preconfidence interval -maturely terminated. All 17 enroled patients (8 using oxycodone, 9 using morphine) completed evaluations. In the oxycodone group, dyspnoea intensity decreased 1.75 points [95% confidence interval, 0.72-2.78] at 60 min and 1.50 points (95% confidence interval, -0.11 to 3.11) at 120 min. In the morphine group, dyspnoea decreased 1.33 points (95% confidence interval, 0.41-2.25) at 60 min and 1.00 point (95% confidence interval, -0.08 to 2.08) at 120 min. The differences did not fulfil the non-inferiority requirement. Although two and four patients in morphine group developed drowsiness at 60 and 120 min, no patient in oxycodone group developed significant adverse events.
Although we did not show the non-inferiority of oxycodone, oxycodone may have some effectiveness for cancer dyspnoea without significant safety concern.
UMIN-CTR: UMIN 000005760.</description><identifier>ISSN: 1465-3621</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyy139</identifier><identifier>PMID: 30260399</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Aged ; Analgesics, Opioid - pharmacology ; Analgesics, Opioid - therapeutic use ; Dyspnea - drug therapy ; Female ; Humans ; Male ; Middle Aged ; Neoplasms - drug therapy ; Oxycodone - pharmacology ; Oxycodone - therapeutic use</subject><ispartof>Japanese journal of clinical oncology, 2018-12, Vol.48 (12), p.1070-1075</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-628135460cf3b938142c7425bea54ef995a57475c9f578ede5984ce627c3239f3</citedby><cites>FETCH-LOGICAL-c442t-628135460cf3b938142c7425bea54ef995a57475c9f578ede5984ce627c3239f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30260399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamaguchi, Takashi</creatorcontrib><creatorcontrib>Matsuda, Yoshinobu</creatorcontrib><creatorcontrib>Matsuoka, Hiromichi</creatorcontrib><creatorcontrib>Hisanaga, Takayuki</creatorcontrib><creatorcontrib>Osaka, Iwao</creatorcontrib><creatorcontrib>Watanabe, Hiroaki</creatorcontrib><creatorcontrib>Maeda, Isseki</creatorcontrib><creatorcontrib>Imai, Kengo</creatorcontrib><creatorcontrib>Tsuneto, Satoru</creatorcontrib><creatorcontrib>Wagatsuma, Yukiko</creatorcontrib><creatorcontrib>Kizawa, Yoshiyuki</creatorcontrib><title>Efficacy of immediate-release oxycodone for dyspnoea in cancer patient: cancer dyspnoea relief (CDR) trial</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Guidelines recommend morphine as the first-line pharmacological treatment for cancer dyspnoea. However, trials with other opioids have not been performed. Our aim was to demonstrate the non-inferiority of oxycodone to morphine for relieving dyspnoea in cancer patients.
We conducted a multicentre, open-label, parallel-group, randomized control trial. We randomly and equally assigned cancer patients on regular oxycodone who developed dyspnoea to get a single dose of oral immediate-release oxycodone or morphine. We evaluated the change in dyspnoea intensity (numeric rating scale: 0-10) and adverse events after the medication administration.
This study was preconfidence interval -maturely terminated. All 17 enroled patients (8 using oxycodone, 9 using morphine) completed evaluations. In the oxycodone group, dyspnoea intensity decreased 1.75 points [95% confidence interval, 0.72-2.78] at 60 min and 1.50 points (95% confidence interval, -0.11 to 3.11) at 120 min. In the morphine group, dyspnoea decreased 1.33 points (95% confidence interval, 0.41-2.25) at 60 min and 1.00 point (95% confidence interval, -0.08 to 2.08) at 120 min. The differences did not fulfil the non-inferiority requirement. Although two and four patients in morphine group developed drowsiness at 60 and 120 min, no patient in oxycodone group developed significant adverse events.
Although we did not show the non-inferiority of oxycodone, oxycodone may have some effectiveness for cancer dyspnoea without significant safety concern.
UMIN-CTR: UMIN 000005760.</description><subject>Adult</subject><subject>Aged</subject><subject>Analgesics, Opioid - pharmacology</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Dyspnea - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Oxycodone - pharmacology</subject><subject>Oxycodone - therapeutic use</subject><issn>1465-3621</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkEtLw0AURgdRbK2u3MssKxI7zyTjTmp9QEEQXYfp5A5OSDJ1JgXz703pA1f3u3A4i4PQNSX3lCg-qyrjZ999T7k6QWMqUpnwlNHTf3uELmKsCCEyF9k5GnHCUsKVGqNqYa0z2vTYW-yaBkqnO0gC1KAjYP_bG1_6FrD1AZd9XLceNHYtNro1EPBadw7a7uHwH5HB4MDi6fzp4xZ3wen6Ep1ZXUe42t8J-npefM5fk-X7y9v8cZkYIViXpCynXIqUGMtXiudUMJMJJlegpQCrlNQyE5k0ysoshxKkyoWBlGWGM64sn6DpzrsO_mcDsSsaFw3UtW7Bb2LBKOUszVPJB_Ruh5rgYwxgi3VwjQ59QUmxjVts4xa7uAN9sxdvVkOoI3uoyf8AX7R2UA</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Yamaguchi, Takashi</creator><creator>Matsuda, Yoshinobu</creator><creator>Matsuoka, Hiromichi</creator><creator>Hisanaga, Takayuki</creator><creator>Osaka, Iwao</creator><creator>Watanabe, Hiroaki</creator><creator>Maeda, Isseki</creator><creator>Imai, Kengo</creator><creator>Tsuneto, Satoru</creator><creator>Wagatsuma, Yukiko</creator><creator>Kizawa, Yoshiyuki</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181201</creationdate><title>Efficacy of immediate-release oxycodone for dyspnoea in cancer patient: cancer dyspnoea relief (CDR) trial</title><author>Yamaguchi, Takashi ; Matsuda, Yoshinobu ; Matsuoka, Hiromichi ; Hisanaga, Takayuki ; Osaka, Iwao ; Watanabe, Hiroaki ; Maeda, Isseki ; Imai, Kengo ; Tsuneto, Satoru ; Wagatsuma, Yukiko ; Kizawa, Yoshiyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-628135460cf3b938142c7425bea54ef995a57475c9f578ede5984ce627c3239f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analgesics, Opioid - pharmacology</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Dyspnea - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Oxycodone - pharmacology</topic><topic>Oxycodone - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamaguchi, Takashi</creatorcontrib><creatorcontrib>Matsuda, Yoshinobu</creatorcontrib><creatorcontrib>Matsuoka, Hiromichi</creatorcontrib><creatorcontrib>Hisanaga, Takayuki</creatorcontrib><creatorcontrib>Osaka, Iwao</creatorcontrib><creatorcontrib>Watanabe, Hiroaki</creatorcontrib><creatorcontrib>Maeda, Isseki</creatorcontrib><creatorcontrib>Imai, Kengo</creatorcontrib><creatorcontrib>Tsuneto, Satoru</creatorcontrib><creatorcontrib>Wagatsuma, Yukiko</creatorcontrib><creatorcontrib>Kizawa, Yoshiyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamaguchi, Takashi</au><au>Matsuda, Yoshinobu</au><au>Matsuoka, Hiromichi</au><au>Hisanaga, Takayuki</au><au>Osaka, Iwao</au><au>Watanabe, Hiroaki</au><au>Maeda, Isseki</au><au>Imai, Kengo</au><au>Tsuneto, Satoru</au><au>Wagatsuma, Yukiko</au><au>Kizawa, Yoshiyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of immediate-release oxycodone for dyspnoea in cancer patient: cancer dyspnoea relief (CDR) trial</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>48</volume><issue>12</issue><spage>1070</spage><epage>1075</epage><pages>1070-1075</pages><issn>1465-3621</issn><eissn>1465-3621</eissn><abstract>Guidelines recommend morphine as the first-line pharmacological treatment for cancer dyspnoea. However, trials with other opioids have not been performed. Our aim was to demonstrate the non-inferiority of oxycodone to morphine for relieving dyspnoea in cancer patients.
We conducted a multicentre, open-label, parallel-group, randomized control trial. We randomly and equally assigned cancer patients on regular oxycodone who developed dyspnoea to get a single dose of oral immediate-release oxycodone or morphine. We evaluated the change in dyspnoea intensity (numeric rating scale: 0-10) and adverse events after the medication administration.
This study was preconfidence interval -maturely terminated. All 17 enroled patients (8 using oxycodone, 9 using morphine) completed evaluations. In the oxycodone group, dyspnoea intensity decreased 1.75 points [95% confidence interval, 0.72-2.78] at 60 min and 1.50 points (95% confidence interval, -0.11 to 3.11) at 120 min. In the morphine group, dyspnoea decreased 1.33 points (95% confidence interval, 0.41-2.25) at 60 min and 1.00 point (95% confidence interval, -0.08 to 2.08) at 120 min. The differences did not fulfil the non-inferiority requirement. Although two and four patients in morphine group developed drowsiness at 60 and 120 min, no patient in oxycodone group developed significant adverse events.
Although we did not show the non-inferiority of oxycodone, oxycodone may have some effectiveness for cancer dyspnoea without significant safety concern.
UMIN-CTR: UMIN 000005760.</abstract><cop>England</cop><pmid>30260399</pmid><doi>10.1093/jjco/hyy139</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-3621 |
| ispartof | Japanese journal of clinical oncology, 2018-12, Vol.48 (12), p.1070-1075 |
| issn | 1465-3621 1465-3621 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2113268653 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Analgesics, Opioid - pharmacology Analgesics, Opioid - therapeutic use Dyspnea - drug therapy Female Humans Male Middle Aged Neoplasms - drug therapy Oxycodone - pharmacology Oxycodone - therapeutic use |
| title | Efficacy of immediate-release oxycodone for dyspnoea in cancer patient: cancer dyspnoea relief (CDR) trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A14%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20immediate-release%20oxycodone%20for%20dyspnoea%20in%20cancer%20patient:%20cancer%20dyspnoea%20relief%20(CDR)%20trial&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Yamaguchi,%20Takashi&rft.date=2018-12-01&rft.volume=48&rft.issue=12&rft.spage=1070&rft.epage=1075&rft.pages=1070-1075&rft.issn=1465-3621&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyy139&rft_dat=%3Cproquest_cross%3E2113268653%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2113268653&rft_id=info:pmid/30260399&rfr_iscdi=true |